Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Iron wins 3 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Likely helps
11 of 15 studies with measurable effects showed benefit.
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
18-45mg elemental iron for deficiency (varies by severity)
On empty stomach if tolerated, Away from tea, coffee, dairy
Ferrous bisglycinate (gentle, well-absorbed) or iron protein succinylate
20 micrograms once daily by subcutaneous injection (the approved osteoporosis dose; PRESCRIPTION ONLY)
any
Subcutaneous injection (prefilled pen)
2-4 weeks
4-8 weeks
4-12 weeks
Over ~18-24 months of daily use
Over ~18-24 months
Detectable by ~3 months
Hours after each dose
Daily oral iron supplementation during pregnancy
The Cochrane database of systematic reviews (2024) · Meta analysis · n=48971
There is probably little to no difference in maternal death (2 versus 4 events, RR 0.57, 95% CI 0.12 to 2.69; 3 trials, 14,060 women; moderate-certainty evidence).
The Prevalence of Anemia among Pregnant Women in China: A Systematic Review and Meta-Analysis
Nutrients (2024) · Meta analysis · n=722
The results showed that the prevalence of anemia, ID, and IDA among pregnant women in China were 30.7% (95% CI: 26.6%, 34.7%), 45.6% (95% CI: 37.0%, 54.2%), and 17.3% (95% CI: 13.9%, 20.7%), respectively.
Treatment for women with postpartum iron deficiency anaemia
The Cochrane database of systematic reviews (2024) · Meta analysis · n=572
Intravenous iron versus oral iron supplementation The evidence is very uncertain about the effect of intravenous iron on mortality (risk ratio (RR) 2.95, 95% confidence interval (CI) 0.12 to 71.96; P = 0.51; I² = not applicable; 3 RCTs; 1 event; 572 women; very low-certainty evidence).
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
N Engl J Med (2001) · Rct · n=1637
Pivotal Fracture Prevention Trial: 1637 postmenopausal women with prior vertebral fractures randomized to PTH(1-34) 20 or 40 microg/day or placebo, median 21 months
Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.
Lancet (2018) · Rct · n=1360
Head-to-head double-blind, double-dummy RCT of teriparatide 20 microg/day vs risedronate 35 mg/week in 1360 women with severe osteoporosis over 24 months
Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
N Engl J Med (2007) · Rct · n=428
18-month randomized, double-blind, controlled head-to-head trial in 428 patients with glucocorticoid-induced osteoporosis
Based on meta-analyses showing hemoglobin improvements of 2.01-5.30 g/dL in iron deficient populations. Higher doses show diminishing returns with increased GI side effects. Effectiveness varies significantly by baseline iron status and form used.
AI-estimated from published studies. Interpret as directional guidance.
Iron has a higher evidence score (9/10 vs 7/10) and wins in 3 of 3 categories.
No known interactions between Iron and Teriparatide have been documented in our database. However, always consult a healthcare provider before combining supplements.